2014 | 4 | 1 | 158-164
Article title

Comparison of expression of selected proteins in the cells of intestinal and diffuse type gastric cancer – immunohistochemical analysis

Title variants
Languages of publication
Introduction: Despite the progress in gaining knowledge about carcinogenesis, it is still unclear what processes are directly responsible for the differentiation of gastric cancer into its intestinal or diffuse form. Dividing of these two forms is based on one of the oldest, yet still commonly used classifications – the classification of Lauren. There are many factors that may influence the formation of gastric tumors of various aggressiveness. Purpose: To evaluate the expression of proteins: fragile histidine triad (FHIT), E-cadherin, α-catenin, γ-catenin, cathepsin B, epidermal growth factor (EGF), HER-2, MMP-9, MCM-2, Bak, Bax, BID, Bcl-XL, p53, FasL, Bcl-2, caspase-8, procaspase-3 in gastric cancer cells, depending on the type of tumor by Lauren classification. Materials and methods: Study group consisted of 91 patients treated surgically for gastric cancer in the Second Department of General and Gastroenterological Surgery, Medical University of Bialystok in years between 2000 and 2006. Results: It is shown, that the expression of E-cadherin was significantly higher in the Lauren I gastric cancer cells than in Lauren II. In case of caspase-8 there has been significantly less frequent expression of this protein in Lauren I gastric cancer cells compared to Lauren II. The authors describe no statistically significant differences in the expression of other proteins taken into consideration. Conclusions: These results suggest the role of adhesion and apoptosis-related proteins in the development of two different types of gastric cancer according to Lauren’s classification.
Physical description
  • Lauren P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbid Scan. 1965;64:31–49.
  • Guo P, Li Y, Zhu Z, Sun Z, Lu C, Wang Z, Xu H. Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients. Tumour Biol. 2013 Apr;34(2):1027-35.
  • Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008 Nov-Dec;28(6A):3815-26.
  • Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 2009 May;21(5):665-74.
  • Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL. Promoter methyltion of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut. 2003 Apr;52(4):502-6.
  • Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol. 2005 Jun 1;90(3):114-33.
  • Jang BG, Kim WH. Molecularpathologyof gastric carcinoma. Pathobiology. 2011; 78(6):302-10.
  • Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.
  • Fiandalo MV, Kyprianou N. Caspase control: protagonists of cancer cell apoptosis. Exp Oncol. 2012 Oct;34(3):165-75.
  • Lee JH, Soung YH, Lee JW, Park WS, Kim SY, Cho YG, Kim CJ, Seo SH, Kim HS, Nam SW, Yoo NJ, Lee SH, Lee JY. Inactivating mutation of the pro-apoptotic gene BID in gastric cancer. J Pathol. 2004 Apr;202(4):439-45.
  • Murhpy GA, Hallday D, McLennan AG. The FHIT tumor suppressor protein regulates the intracellular concentration of diadenosine triphosphatase but not diadenosine tetrapho-sphate. Cancer Res. 2000 May 1;60(9):2334-42.
  • Rocco A1, Schandl L, Chen J, Wang H, Tulassay Z, McNamara D, Malfertheiner P, Ebert MP. Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8.
  • Kawaguchi K, Yashima K, Koda M, Tsutsumi A, Kitaoka S, Andachi H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Murawaki Y. Fhit expre-ssion in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype. Br J Cancer. 2004 Feb;90(3):672-7.
  • Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overexpression of matrix metallo-proteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res. 2000 Sep;6(9):3581-4.
  • Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metallo-proteinase-9 and tissue inhibitor of metallo-proteinase-1 in invasiveness and meta-stasis of human gastric carcinoma. World J Gastro-enterol. 2003 May;9(5):899-904.
  • Hong L, Han Y, Yang J, Zhang H, Jin Y, Brain L, Li M, Zhao Q. Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene. 2013 Oct 15;529 (1):69-72.
  • Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, Wei W, Xu WP. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013 Jul;44(5):380-9.
  • Ebert MP, Krüger S, Fogeron ML, Lamer S, Chen J, Pross M, Schulz HU, Lage H, Heim S, Roessner A, Malfertheiner P, Röcken C. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics. 2005 Apr;5(6):1693-704.
  • Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 2005 Feb;52(1-2):1-9.
  • Yang C, Wen Y, Li H, Zhang D, Zhang N, Shi X, Jiang B, Ma X, Yang P, Tang H, Peng Z, Yang Y. Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer. Oncol Rep. 2012; 27(1):135-142.
  • Karim S, Mirza Z, Naseer MI, Al-Qahtani MH, Ali A. Clinicopathological characteristics and chronology of p53 expression in the development of gastric cancer. Hepatogastro-enterology. 2013 Nov-Dec;60(128):2113-8.
  • Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res. 2011;110:107-39.
  • Frejlich E, Rudno-Rudzińska J, Janiszewski K, Salomon L, Kotulski K, Pelzer O, Grzebieniak Z, Tarnawa R, Kielan W. Caspases and their role in gastric cancer. Adv Clin Exp Med. 2013 Jul-Aug;22(4):593-602.
  • Yoo NJ1, Kim HS, Kim SY, Park WS, Kim SH, Lee JY, Lee SH. Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. APMIS. 2002 Nov;110(11):825-32.
  • Soung YH1, Lee JW, Kim SY, Jang J, Park YG, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 2005 Feb 1;65(3):815-21.
  • Gomes TS, Oshima CT, Segreto HR, Barrazueta LM, Costa HO, Lima FO, Forones NM, Ribeiro DA. The extrinsic apoptotic signaling pathway in gastric adenocarcinomas assessed by tissue microarray. Pathol Res Pract. 2011 Oct 15; 207(10):613-7.
  • Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327-49.
  • Nadauld LD, Ford JM. Molecular profiling of gastric cancer: toward personalized cancer medicine. J Clin Oncol. 2013 Mar 1;31(7):838-9.
  • Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49-95.
  • Yu XW, Xu Q, Xu Y, Gong YH, Yuan Y. Expression of the E-cadherin/β-catenin/tcf-4 pathway in gastric diseases with relation to Helicobacter pylori infection: clinical and pathological implications. Asian Pac J Cancer Prev. 2014;15(1):215-20.
  • Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol. 2003 Dec;14(12): 1705-13.
  • Warneke VS, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MP, Lordick F, Röcken C. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol. 2013 Sep;22(3): 127-37.
  • Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med. 2012 Jun;136(6):691-7.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.